Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Intra-Arterial (IA) Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma (ACPP) and Choroid Plexus Carcinoma (CPC) Prior to Second-Look Surgery

Clinical Trial Details

Atypical choroid plexus papilloma (ACPP) and choroid plexus carcinoma (CPC) are both primary brain tumors that begin near the brain tissue. Choroid plexus carcinoma is fast-growing high-grade tumor, whereas atypical choroid plexus papilloma is an intermediate-grade tumor.

Removing these tumors through surgery has the best outcome for patients with ACPP or CPC, but there are often complications that can occur during the surgery. 

The purpose of this study is to better understand if a single dose of inter-arterial (IA) chemotherapy is safe in patients with atypical choroid plexus papilloma or choroid plexus carcinoma. This research also aims to better understand if IA chemotherapy would reduce the size/volume of the tumor, reduce blood loss during surgical removal of ACPP or CPC, and to see if pre-surgical IA chemotherapy would help make surgical removal of the tumor more likely to be successful. 

Participants in this study will receive a single dose of triple combination chemotherapy delivered directly to the tumor site through intra-arterial direct-drug delivery technique prior to second-look surgery. By giving IA chemotherapy before surgery, this study hopes to reduce the size of the tumor and decrease blood loss, which may lead to more successful removal of the tumor during surgery.



Key Eligibility: 

1. Participants must have a confirmed diagnosis of ACPP or CPP that is either newly diagnosed, residual, or recurrent.
2. Participants must not have any severe treatment related toxicities if they received prior treatment
3. Participants with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.

Detailed eligibility criteria will be discussed with the study team.

Study contact by location

Upper East Side - Manhattan


Colleen Sanders

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group

Adult , Pediatric